Palvella Therapeutics (PVLA) Long-Term Investments (2017 - 2022)
Palvella Therapeutics (PVLA) posted quarterly Long-Term Investments of $4.5 million for Q2 2022, down 49.54% quarter-over-quarter from $9.0 million in Q3 2020.
Palvella Therapeutics (PVLA) Long-Term Investments (2017 - 2022) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Long-Term Investments for 5 consecutive years, with $4.5 million the latest figure, recorded in Q2 2022.
- In Q2 2022, Long-Term Investments changed N/A year-over-year to $4.5 million; the TTM figure through Jun 2022 stood at $4.5 million (changed N/A YoY), while the FY2019 annual figure was $28.6 million, up 397.46% from the prior year.
- Long-Term Investments eased to $4.5 million in Q2 2022 per PVLA's latest filing, from $9.0 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $38.9 million in Q1 2019 and bottomed at $700000.0 in Q2 2018.
- Historically, Long-Term Investments has averaged $10.4 million across 4 years, with a median of $5.7 million in 2018.
- Annual changes were most pronounced in 2019 — Long-Term Investments soared 1406.93% — and 2020, when it slumped 85.32%.
- Palvella Therapeutics' Long-Term Investments stood at $5.8 million in 2018, then soared by 397.46% to $28.6 million in 2019, then plunged by 68.58% to $9.0 million in 2020, then sank by 49.54% to $4.5 million in 2022.
- Business Quant data shows PVLA's Long-Term Investments at $4.5 million in Q2 2022, $9.0 million in Q3 2020, and $1.6 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 4.54 Mn |
| Sep 30, 2020 | 9.00 Mn |
| Jun 30, 2020 | 1.57 Mn |
| Mar 31, 2020 | 5.71 Mn |
| Dec 31, 2019 | 28.64 Mn |
| Jun 30, 2019 | 6.59 Mn |
| Mar 31, 2019 | 38.92 Mn |
| Dec 31, 2018 | 5.76 Mn |
| Jun 30, 2018 | 700,000.00 |
| Mar 31, 2018 | 2.58 Mn |
| Dec 31, 2017 | 9.92 Mn |